Confirmation of administrative claims‐identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease‐modifying antirheumatic drugs
Open Access
- 28 February 2007
- journal article
- contribution from-the-field
- Published by Wiley in Arthritis Care & Research
- Vol. 57 (2) , 343-346
- https://doi.org/10.1002/art.22544
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pneumocystis carinii Pneumonia During Maintenance Anti–Tumor Necrosis Factor-α Therapy with Infliximab for Crohn’s DiseaseInflammatory Bowel Diseases, 2004
- Pharmacy Data for Tuberculosis Surveillance and Assessment of Patient ManagementEmerging Infectious Diseases, 2004
- Pneumocystis Jiroveci (Carinii) Pneumonia Following Initiation of Infliximab and Azathioprine Therapy in a Patient With Crohnʼs DiseaseInflammatory Bowel Diseases, 2004
- Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsAmerican Heart Journal, 2004
- Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonistsArthritis & Rheumatism, 2004
- Agreement between patient self-report and a Veterans Affairs national pharmacy database for identifying recent exposures to antibioticsPharmacoepidemiology and Drug Safety, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- A new method for identifying antibiotic-treated infections using automated pharmacy recordsJournal of Clinical Epidemiology, 2000
- Efficient Identification of Postdischarge Surgical Site Infections: Use of Automated Pharmacy Dispensing Information, Administrative Data, and Medical Record InformationThe Journal of Infectious Diseases, 1999